Author

Stacey M. Anderson

Observed names: S M Anderson, S M. Anderson, S. M. Anderson, S.M. Anderson, STACEY ANDERSON, Stacey Anderson, Stacey M Anderson

Observed institutions: University of Virginia Health System, Yale University, Sansum Diabetes Research Institute, University of Virginia Medical Center, Stanford Medicine, Jaeb Center for Health Research, University of Virginia, The Ohio State University, Stanford University

ORCID: 0000-0001-6462-1779

Observed ORCID: 0000-0001-6462-1779

OpenAlex ID: A5081776751

Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes

2019 · Sue A. Brown, Boris P. Kovatchev, et al. · New England Journal of Medicine · 1,025

PDF

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes

2017 · Satish K. Garg, Stuart A. Weinzimer, et al. · Diabetes Technology & Therapeutics · 585

Fully Integrated Artificial Pancreas in Type 1 Diabetes

2012 · Marc Breton, Anne Farret, et al. · Diabetes · 316

Comparison of the Numerical and Clinical Accuracy of Four Continuous Glucose Monitors

2008 · Boris Kovatchev, Stacey Anderson, et al. · Diabetes Care · 236

PDF

Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the Results

2010 · Boris Kovatchev, Claudio Cobelli, et al. · Journal of Diabetes Science and Technology · 200

Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: The Virginia Experience

2009 · William L. Clarke, Stacey Anderson, et al. · Journal of Diabetes Science and Technology · 185

Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas

2014 · Boris P. Kovatchev, Eric Renard, et al. · Diabetes Care · 178

Feasibility of Outpatient Fully Integrated Closed-Loop Control

2013 · Boris P. Kovatchev, Eric Renard, et al. · Diabetes Care · 177

Evaluating the Clinical Accuracy of Two Continuous Glucose Sensors Using Continuous Glucose–Error Grid Analysis

2005 · William L. Clarke, Stacey Anderson, et al. · Diabetes Care · 155

PDF

Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery

2016 · Boris Kovatchev, Peiyao Cheng, et al. · Diabetes Technology & Therapeutics · 141

Adding Heart Rate Signal to a Control-to-Range Artificial Pancreas System Improves the Protection Against Hypoglycemia During Exercise in Type 1 Diabetes

2014 · Marc D. Breton, Sue A. Brown, et al. · Diabetes Technology & Therapeutics · 128

Multinational Home Use of Closed-Loop Control Is Safe and Effective

2016 · Stacey M. Anderson, Dan Raghinaru, et al. · Diabetes Care · 120

PDF

Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial

2020 · Elvira Isganaitis, Dan Raghinaru, et al. · Diabetes Technology & Therapeutics · 115

Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes Mellitus

2018 · Marc D. Breton, Stephen D. Patek, et al. · Diabetes Technology & Therapeutics · 98

Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia

2017 · Eyal Dassau, Jordan E. Pinsker, et al. · Diabetes Care · 85

Neurophysiological regulation andtarget-tissue impact of the pulsatile mode of growth hormone secretion in the human

2001 · Johannes D. Veldhuis, Stacey M. Anderson, et al. · Growth Hormone & IGF Research · 82

Short-Term Estradiol Supplementation Augments Growth Hormone (GH) Secretory Responsiveness to Dose-Varying GH-Releasing Peptide Infusions in Healthy Postmenopausal Women1

2001 · S. M. Anderson, N. Shah, et al. · The Journal of Clinical Endocrinology & Metabolism · 79

2021 · Erin C. Cobry, Lauren G. Kanapka, et al. · Diabetes Technology & Therapeutics · 71

Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial

2021 · Yogish C. Kudva, Lori M. Laffel, et al. · Diabetes Technology & Therapeutics · 68

Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia

2019 · Stacey M. Anderson, Bruce A. Buckingham, et al. · Diabetes Technology & Therapeutics · 68

Lowering Total Plasma Insulin-Like Growth Factor I Concentrations by Way of a Novel, Potent, and Selective Growth Hormone (GH) Receptor Antagonist, Pegvisomant (B2036-Peg), Augments the Amplitude of GH Secretory Bursts and Elevates Basal/Nonpulsatile GH Release in Healthy Women and Men1

2001 · J. D. Veldhuis, M. Bidlingmaier, et al. · The Journal of Clinical Endocrinology & Metabolism · 68

Modeling of Calibration Effectiveness and Blood-to-Interstitial Glucose Dynamics as Potential Confounders of the Accuracy of Continuous Glucose Sensors during Hyperinsulinemic Clamp

2007 · Christopher King, Stacey M. Anderson, et al. · Journal of Diabetes Science and Technology · 66

Multinight “Bedside” Closed-Loop Control for Patients with Type 1 Diabetes

2015 · Sue A. Brown, Boris P. Kovatchev, et al. · Diabetes Technology & Therapeutics · 64

Predictors of Time-in-Range (70–180 mg/dL) Achieved Using a Closed-Loop Control System

2021 · Melissa J. Schoelwer, Lauren G. Kanapka, et al. · Diabetes Technology & Therapeutics · 63

Impact of Experimental Blockade of Peripheral Growth Hormone (GH) Receptors on the Kinetics of Endogenous and Exogenous GH Removal in Healthy Women and Men

2002 · J. D. Veldhuis, M. Bidlingmaier, et al. · The Journal of Clinical Endocrinology & Metabolism · 61

Works count: 88

Citation count: 6,020

H-index: 41

I10-index: 67